Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR

Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that has been approved for the treatment of metastatic non-small cell lung cancer (NSCLC) positive for the secondary T790M mutation of EGFR. In a preclinical study, it also showed efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Hitomi, Hayashi, Hidetoshi, Iwasa, Tsutomu, Hasegawa, Yoshikazu, Takeda, Masayuki, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559906/
https://www.ncbi.nlm.nih.gov/pubmed/28848674
http://dx.doi.org/10.1136/esmoopen-2016-000104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559906/
https://www.ncbi.nlm.nih.gov/pubmed/28848674
http://dx.doi.org/10.1136/esmoopen-2016-000104

Ejemplares similares